Prognostic utility of novel biomarkers in aortic valve stenosis

Simple item page
dc.contributor.authorTretjakovs, Peteris
dc.contributor.authorHofmanis, Juris
dc.contributor.authorHofmane, Dace
dc.contributor.authorKrieviņa, Gita
dc.contributor.authorBlumfelds, Leons
dc.contributor.authorMackevičs, Vitolds
dc.contributor.authorLejnieks, Aivars
dc.contributor.authorBahs, Guntis
dc.contributor.institutionFaculty of Medicine
dc.date.accessioned2021-04-28T09:30:01Z
dc.date.available2021-04-28T09:30:01Z
dc.date.issued2019-05-01
dc.descriptionFunding Information: This study was supported in part by grant No. 2014.10-4/VPP-1.1.2 of the framework of the Latvian National Programme. Publisher Copyright: © 2019 Peteris Tretjakovs et al., published by Sciendo 2019.
dc.description.abstractThe aim of the present study was to evaluate plasma levels of chemerin, myeloperoxidase (MPO), fibroblast growth factor-21 (FGF-21), thioredoxin reductase-1 (TrxR1), and matrix metallopeptidase-9 (MMP-9) in acquired aortic valve (AoV) stenosis patients to determine correlations between the studied cellular factors, and also clarify the predictive values of these factors as biomarkers in AoV stenosis. AoV stenosis patients were classified into three groups: 17 patients with mild AoV stenosis; 19 with moderate and 15 with severe AoV stenosis. Twenty-four subjects without AoV stenosis were selected as a control group. Our findings suggest that AoV stenosis might be associated with increased chemerin, TrxR1, MPO, and FGF-21 levels in plasma. Moreover, these factors and also MMP-9 already reached statistically significantly elevated levels in the early stages of AoV stenosis, but MPO levels were more pronounced in patients with moderate and severe AoV stenosis. Chemerin was correlated with all of the studied cytokines; TrxR1 and MMP-9 were correlated with several other cellular factors. Our findings (by ROC analysis) suggest that MPO and chemerin might serve as specific and sensitive biomarkers for AoV stenosis without grading the severity, but, in relation to mild AoV stenosis, TrxR1, FGF-21, and MMP-9 also reached good or moderate levels as biomarkers. The cellular factors might serve as novel diagnostic and prognostic biomarkers in AoV stenosis patients, while chemerin and MPO may be more powerful.en
dc.description.statusPeer reviewed
dc.format.extent7
dc.format.extent360176
dc.identifier.citationTretjakovs, P, Hofmanis, J, Hofmane, D, Krieviņa, G, Blumfelds, L, Mackevičs, V, Lejnieks, A & Bahs, G 2019, 'Prognostic utility of novel biomarkers in aortic valve stenosis', Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, vol. 73, no. 2, pp. 100-106. https://doi.org/10.2478/prolas-2019-0016
dc.identifier.doi10.2478/prolas-2019-0016
dc.identifier.issn1407-009X
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/3964
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85065655590&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofProceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectaortic valve stenosis
dc.subjectchemerin
dc.subjectfibroblast growth factor-21
dc.subjectmatrix metalloproteinase-9
dc.subjectmyeloperoxidase
dc.subjectthioredoxin reductase-1
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral
dc.titlePrognostic utility of novel biomarkers in aortic valve stenosisen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PROGNOSTIC_UTILITY_OF_NOVEL_BIOMARKERS.pdf
Size:
351.73 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure